Key result
Aspirin deprescription occurs in only ~9% of patients following gastrointestinal bleeding.
Why the study?
Aspirin for primary cardiovascular prevention is rarely deprescribed at discharge in patients hospitalized with gastrointestinal bleeding despite guidelines recommending against its use in this population.
Answers are grounded in this paper and cite their sources.
Editors, We read with great interest the recent retrospective realworld study by Li et al1 reporting that aspirin for primary cardiovascular prevention was rarely (9.0%) deprescribed at discharge in patients hospitalised with gastrointestinal bleeding (GIB). This does not adhere to the current guideline recommending against aspirin for primary prevention of cardiovascular events in individuals with a history of GIB. The authors also provided reasons for this phenomenon, including patientlevel barriers, and physicianand systemsbased barriers. However, other factors should also be taken into consideration. First, the causes of GIB were not described in Li's study. Therefore, whether the incidence of GIB was associated with aspirin use could not be identified. If aspirin did not directly lead to the GIB event, then gastroenterologists and patients may be reluctant to discontinue aspirin after discharge. Second, the duration of aspirin use should also be considered. New aspirin users have a higher risk of GIB than chronic aspirin users, particularly during the initial 6 months.2 Thus, new aspirin users with subsequent GIB could be more likely to discontinue aspirin after discharge. Third, in Li's study, the prevalence of diabetes among the patients who continued aspirin was significantly higher than in those in whom aspirin was deprescribed. The prescription of aspirin for patients with diabetes but without atherosclerotic cardiovascular disease is common. An analysis of US National Health and Nutrition Examination Survey demonstrated that, among diabetic patients without atherosclerotic cardiovascular disease, 42.1% (95% CI: 37.2%– 47.1%) took aspirin under a doctor's advice, and only 4.3% (95% CI: 2.5%– 7.3%) take it on their own.3 A metaanalysis of randomised controlled trials revealed that aspirin use in patients with diabetes reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction and stroke compared with placebo. However, the routine use of aspirin for primary prevention among diabetic patients cannot be advised due to the increased risk of major bleeding.4 These results suggest that both physician and patient education about the indication for aspirin use for primary prevention should be strengthened. We congratulate Dr. Li et al on their novel study. Collaboration between gastroenterologists, cardiologists and other specialists will be important to improve adherence to guidelines. AUTHOR CONTRIBUTIONS Jian Zhao: Conceptualization (lead); funding acquisition (lead); investigation (lead); methodology (lead); resources (lead); supervision (lead); writing – original draft (lead); writing – review and editing (lead). Kun Huang: Conceptualization (equal); methodology (equal); writing – original draft (equal). Bowen Hu: Conceptualization (equal); investigation (equal); writing – original draft (equal).
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2023) conducted a letter in Gastrointestinal bleeding. Aspirin was evaluated. This letter highlights that factors including the cause of bleeding, duration of use, and concurrent diabetes may explain the rare deprescription of aspirin after gastrointestinal bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: